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Abstract
Neurofascin was recently reported as a target for axopathic autoantibodies in patients with multiple sclerosis (MS), a
response that will exacerbate axonal pathology and disease severity in an animal model of multiple sclerosis. As
transplacental transfer of maternal autoantibodies can permanently damage the developing nervous system we
investigated whether intrauterine exposure to this neurofascin-specific response had any detrimental effect on white matter
tract development. To address this question we intravenously injected pregnant rats with either a pathogenic anti-
neurofascin monoclonal antibody or an appropriate isotype control on days 15 and 18 of pregnancy, respectively, to mimic
the physiological concentration of maternal antibodies in the circulation of the fetus towards the end of pregnancy. Pups
were monitored daily with respect to litter size, birth weight, growth and motor development. Histological studies were
performed on E20 embryos and pups sacrificed on days 2, 10, 21, 32 and 45 days post partum. Results:
Immunohistochemistry for light and confocal microscopy confirmed passively transferred anti-neurofascin antibody had
crossed the placenta to bind to distinct structures in the developing cortex and cerebellum. However, this did not result in
any significant differences in litter size, birth weight, or general physical development between litters from control mothers
or those treated with the neurofascin-specific antibody. Histological analysis also failed to identify any neuronal or white
matter tract abnormalities induced by the neurofascin-specific antibody. Conclusions: We show that transplacental transfer
of circulating anti-neurofascin antibodies can occur and targets specific structures in the CNS of the developing fetus.
However, this did not result in any pre- or post-natal abnormalities in the offspring of the treated mothers. These results
assure that even if anti-neurofascin responses are detected in pregnant women with multiple sclerosis these are unlikely to
have a negative effect on their children.
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Introduction
Neurofascin (Nfasc) is a cell adhesion molecule belonging to the
immunoglobulin superfamily (IgSF). Several neurofascin isoforms
are generated by alternative splicing (155 kDA, 166, 180 and
186 kDa) and their expression is temporally and spatially regulated
during development in the central [1–4] and peripheral nervous
system [5,6]. Neuronal neurofascin (Nfasc186) is localized at the
nodes of Ranvier and axonal initial segments (AIS) of myelinated
fibers where it interacts with voltage gated sodium channels and
other proteins such as ankyrin G and ß IV-Spectrin [7,8]. In
contrast, neurofascin-155 (Nfasc155) is an oligodendroglial prod-
uct [9] sequestered in septate-like junctions where the paranodal
loops of the myelin sheath contact the axonal surface. Nfasc155
interacts with the axonal Caspr-Contactin complex at these sites
[10] to form electron dense assemblies characteristic of this
paranodal junction complex. These complexes play a critical role
in maintaining saltatory conduction by physically separating
NaV1.6 channels at the node from Kv1.1 and 1.2 potassium
channels located within the juxtaparanodal domain of the
axolemma [11,12].
Apart from the voltage gated sodium channel the neurofascins
remain the only proteins known to be essential for nodal assembly
and saltatory conduction in the central nervous system [13,14]. It
therefore not surprising that perturbation of neurofascin expres-
sion has dramatic pathophysiological consequences [11]. Neuro-
fascin- null mice exhibit severe ataxia, motor paresis and severe
reduction of nerve conduction velocities and have a dramatically
reduced life span of only 3 weeks [13,15]. They neither form
paranodal adhesion junctions nor nodal complexes [11]. Selective
genetic ablation of Nfasc186 during development results in nodal
disorganization, including loss of Na(v) channel and ankyrin-G
(AnkG) enrichment at nodes [12], as well as neuron degeneration
and severe ataxia [16]. After completion of development,
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neurofascin is believed to anchor key elements of the adult AIS
complex [14]. Loss of neurofascin expression by adult neurons
leads to slow disorganization of the AIS and pinceau morphology
[16] with consequent impairment of motor learning and abolition
of the spontaneous tonic discharge typical of purkinje cells [14].
Similarly, ablation of glial Nfasc155 in adult myelinating glia leads
to a gradual disorganization of paranodal axoglial junctions as the
levels of neurofascin protein at the paranodes decline [15].
Changes in the distribution of neurofascin isoforms in the nodal
domains of myelinated axons are also seen in multiple sclerosis
(MS) lesions [1,17].
Neurofascin is also a target for autoantibodies, as demonstrated
by the presence of neurofascin-specific autoantibodies in patients
with MS [18,19], Guillain-Barre syndrome [20], and chronic
idiopathic demyelinating neuropathy [21,22]. In an animal model
of multiple sclerosis these antibodies were shown to aggravate
disease severity by disrupting axonal conduction, triggering axonal
injury and inhibiting remyelination [18,23–25].
Previous studies in myasthenia gravis and systemic lupus
erythematosus demonstrate transplacental exposure to maternal
autoantibody can mediate severe effects on the developing fetus
[26–28]. Given the diverse and vital role of neurofascin during
development of the central and the peripheral nervous system we
speculated anti-neurofascin antibodies might have negative effects
on fetal development. Although there is no obvious clinical
evidence for increased negative outcome of pregnancies in
mothers with MS subtle differences might have gone undetected
thus far. In our study we sought to address this question by
passively immunizing pregnant rats with a pan-neurofascin
antibody derived from the mouse.
Materials and Methods
Antibody generation
A12/18.1 hybridoma cells secreting a pan-Nfasc monoclonal
mouse IgG2a antibody (as described in [18]) were cultured in
CELLineH cell culture flasks (BD biosciences) following manufac-
turer’s guidelines. The media compartment was filled with 200 ml
complete DMEM containing 10% fetal calf serum, 2 mM L-
glutamine (200 mM), 1 mM sodium pyruvate, 50 mM ß-mercap-
toethanol, 1% non-essential amino acids and 1% penicillin/
streptomycin and the cell compartment inoculated with 26106
cells/ml diluted in complete DMEM. Supernatant was harvested
from the cell compartment after 7 days and twice a week
thereafter. Supernatants were centrifuged and stored at 220uC.
Antibody production was monitored by ELISA and mAb purified
from pooled supernatants by protein G chromatography.
Animals
Twenty 8–10 weeks old pregnant Sprague Dawley rats obtained
from Versuchstierzuchtanstalt Himberg/Medical University of
Vienna and were housed in the animal facility of the Institute for
Biomedical Research/Medical University Graz in groups of two
rats/cage with access to food and water at libitum. On days E15
and E18 of pregnancy rats were intravenously injected with either
1 mg anti-neurofascin monoclonal antibody (10 rats; antibody
generated as described above) or the same dose of a commercially
available mouse IgG2a myeloma protein (8 rats, Sigma- Aldrich,
St.Louis, MO) as an isotype control not directed against any
central nervous system antigen. One pregnant rat received 0,5 mg
anti-neurofascin antibody on days E15 and E18, respectively;
another pregnant rat did not undergo any treatment and its
offspring were used as controls for weight and motor development.
For the injections the rats were briefly anaesthetized with
isoflurane. On day E20, two rats of the neurofascin antibody
treated group and one of the control antibody group were deeply
anesthetized with isoflurane and sacrificed by cervical dislocation
for histological analysis of the pups. The pups were sacrificed by
decapitation. The remaining pregnant rats were allowed to give
birth to their offspring; these were monitored by daily observation
by two blinded investigators with respect to litter size, birth weight,
growth curve and motor development up to day 32. For
histological analysis of the fully mature rat central nervous system,
some rats were kept until 45 days of age. In total, 236 pups were
analysed in this experiment. The number of pups and their
respective age at sacrifice and subsequent histological analysis is
shown in Table 1. The animal experiment was approved by the
Table 1. Number of pups analysed with respect of
developmental stage.
E20 p2 p10 p15 p21 p32 p42
anti-neurofascin
antibody 261mg
27 20 25 31 20 15 15
anti neurofascin
antibody 260,5mg




7 11 5 5 5 14 5
untreated control 12
pups total 34 35 35 40 28 41 23
E20 means day 20 of gestation, p2, p10, p15, p21, p32, p42 represents the
respective age in days (postnatal days) at time of sacrifice.
doi:10.1371/journal.pone.0085393.t001
Figure 1. Neurofascin antibodies pass the placental border and
reach fetal tissues. Histological analysis of pups (developmental
stage E20) 48 hours after application of the second dose of passive
antibody transfer. Immunohistochemistry for mouse-immunoglobulin
proves antibody transfer into fetal tissue. (a) shows mouse immuno-
globulin reactivity in brain tissue vessels of the unborn rat pups, (b) in
fetal liver, (c) in the kidney and (d) in the lung of the pups (original
magnification 2006). Scale bars represent 50 mm.
doi:10.1371/journal.pone.0085393.g001
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Austrian ministry of Science and Research (GZ 66.010/0056-II/
10b/2010). All efforts were made to minimize suffering of the
animals.
Tissue processing and immunohistochemistry
On days E20 and postnatal day(p) p2, p10, p21, p32 and p45
groups of pups were sacrificed; E20 and p2 pups were decapitated,
p10, p21, p32 and p45 pups were deeply anesthetized with
isoflurane, sacrificed through cervical dislocation and then
perfused transcardially with 4% PFA. Brains and spinal cords
were postfixed in 4%PFA over 24 hours and embedded in
paraffin. Serial sections of 2–3mm were cut using a microtome.
After deparaffinization in XEM-200 for 20 min (Vogel GmbH,
Giessen, Germany) and washing in alcohol solutions of decreasing
Figure 2. Neurofascin immunoreactivity is not altered by
intrauterine exposure to anti- neurofascin autoantibodies.
Immunohistochemistry for neurofascin in the normal adult rat brain
(a-d) and at different stages of development after intrauterine exposure
to the anti- neurofascin antibody (e-i). Areas marked with a rectangle in
Fig. 2a and b are shown at higher magnification in c and d, respectively.
(a, c) shows immunoreactivity for neurofascin in axons in the
hippocampus region, (b, d) in purkinje cells of the cerebellum of
normal, untreated adult rats. (e) shows neurofascin staining in the
hippocampus region in rats at E20, (f, g) in purkinje cells at postnatal
day 10, (h) in purkinje cells at p 21 and (i) in axons of the hippocampus
at p21. The arrows in 2d, f-h show the specific neurofascin
immunoreactivity of the initial axonal segments of the purkinje cells.
(original magnification in a, b 1006, in c-i 6306). Scale bars in a, b
represents 100 mm, in c-i 20 mm.
doi:10.1371/journal.pone.0085393.g002
Figure 3. Neurofascin antibodies bind to their target structures
in the fetal rat brain. Double stainings for light microscopy for
neurofascin (brown) and mouse IgG (red) in rats at p21 are shown in
Fig. 3 a-d. In neurofascin antibody treated rats (3a, c) an intense double
staining for neurofascin as well as mouse Ig is detectable in axons of the
hippocampus region (a) and purkinje cells (c), proving the mouse-
derived anti-neurofascin antibody bound to its target structures.
Animals treated with control antibody (3b, d) show reactivity for
neurofascin in the respective areas, but no staining for mouse
immunoglobulin. The black arrows in 3 c, d show the initial axonal
segments of the purkinje cells. This staining pattern is confirmed by
immunohistochemistry for confocal microscopy of the hippocampus
region; staining pattern for neurofascin (e, g) is identical in neurofascin
antibody treated animals (e) and control animals (g), but mouse
immunoglobulin is only detectable in the neurofascin group (f) but not
in the control group (h). Scale bars in a-d represent 20 mm, and in e-h
100 mm.
doi:10.1371/journal.pone.0085393.g003
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concentrations (from 96%/70%/50% to deionized water). Sec-
tions were stained with hematoxylin/eosin and luxol fast blue to
assess gross developmental abnormalities.
In adjacent serial sections immunohistochemistry was per-
formed according to the following protocol: Antigen retrieval was
performed by heating slides in citrate buffer at pH 6.0 for one
hour in a commercial food steamer. After cooling and washing in
phosphate buffered saline (PBS), slides were incubated over night
with antibodies either directed against neurofascin (generated as
described above) at a dilution of 1:50 or anti-mouse IgG (GE
Healthcare, Buckinghamshire, UK) at a dilution of 1:200. The
antibodies were diluted in 10% fetal calf serum/PBS. Bound
primary antibody was detected with a biotin–avidin technique
using 3,39-diaminobenzidine tetra-hydrochloride (Sigma, St.
Louis, MA) as chromogen as previously described in detail [29].
Control sections were incubated in the absence of primary
antibody.
Furthermore double staining for neurofascin/mouse IgG was
performed for light microscopy.
Neurofascin immunoreactivity (IR) was visualized using a
biotin-avidin technique as described above with diaminobenzidine
enhanced by Nickel/cobalt as chromogen. The second primary
antibody was detected with the biotin-avidin technique using 3-
amino-9-ethyl-carbazole (Sigma, St. Louis, MO) as chromogen.
Confocal laser microscopy
For confocal microscopy, anti-neurofascin antibody was applied
at a dilution of 1:100 at 4uC in a wet chamber over night. After
washing with phosphate buffered saline (PBS) biotinylated anti-
mouse IgG (GE Healthcare, Buckinghamshire, UK) was applied
for 1 hour at room temperature at a dilution of 1:200, followed by
Avidin HRP (1:100; Sigma, St. Louis, USA) for one 1 hour. After
enhancement with 0,1% CSA in PBS/0.03% H2O2 for 20 min at
room temperature (protocol as described in [30]) signal was
visualized by Avidin-Cy2 (Jackson ImmunoResearch, West Grove,
PA, USA) at 1:75 for one hour at room temperature. For detection
of bound anti-neurofascin antibody in fetal tissue slides were
subjected to the protocol as described above but without applying
the anti- neurofascin antibody in the first step. Fluorescent
preparations were examined using a Leica TCS SP5 laser
scanning microscope with LAS AF software (Leica Microsystems,
CMS GmbH, Germany). An argon laser was used for detection of
Cy2 (488 nm excitation) signal.
Figure 4. Graphical presentation of vital statistics of neurofascin treated pups vs. control groups. The weight curve from age p2 up to
p32 of neurofascin- and control antibody treated pups in comparison to an untreated control rat litter is shown in Fig. 4 a. Weight curves are
remarkably similar with no significant differences noted. Also, the litter sizes did not differ significantly between the neurofascin antibody group and
the control antibody group (p= 0,336712), as shown in Fig. 4 b, ruling out significant fetal loss due to the presence of the antiaxonal antibody. Fig. 4c
shows the mean times in seconds +2 SD on an accelerating Rotarod device tested on postnatal days 16, 19, 24, 25 and 32. Again, no statistical
significant difference between the groups was found (untreated control vs. control antibody group p= 0,530163, untreated control vs. neurofascin
treatment p= 0,354292, control antibody group vs. neurofascin group p=0,117562). Fore limb grip test was performed on postnatal days 24, 25 and
32 and is shown in Fig. 4d. Again, no statistically significant differences were noted (untreated control vs. control antibody group p=0,935596,
untreated control vs. neurofascin treatment p= 0,429921, control antibody group vs. neurofascin group p=0,593029).
doi:10.1371/journal.pone.0085393.g004
Neurofascin- Autoantibodies and Fetal Development
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Accelerated rotarod performance test
The rotarod test is a common test to assess motor coordination
and balance alterations in the rodent. At age p16, p19, p24, p25
and p32, rats of all three groups (neurofascin treated, control
antibody treated and untreated control) were placed on a
commercially available rotarod device (IITC Life Sciences Series
8, www.iitcinc.com), consisting of a rotating rod (diameter 3 L
inch) situated 20 cm high above a tilting plank. Before the
beginning of the sessions, all animals were allowed to habituate
with the apparatus during 30 s with no rotation. Then, the speed
of rotation gradually increased from 0 to 30 rpm and the time until
falling off the rod was measured. Rats were tested three times in
each session and the best performance of each rat was collected.
Grip strength test
To assess the fore limb grip strength of rats of all three
experimental groups were placed on a commercially available
Grip strength meter (TSE Systems, www.tse-systems.com) on days
p24, p25 and p32. In brief, a grid is connected to a sensor. The
rats are held by the tail and lowered over the top of the grid so that
only their front paws can grip the grid. The animals cling to the
mesh by a natural reflex. The torso of the rat is then held
horizontal and pulled back steadily by the observer until the
animal releases the grid. The maximal grip strength value is
measured. Each animal was tested three times at each session and
the best value of each session was collected.
Statistical analysis
Litter size, weight data and motor test results are expressed as
mean +2 SD. Differences between the groups were assessed pair
wise by a parametric univariate t-test. The analyses were
performed using Statgraphic software (www.statgraphics.com).
The level of p,0.05 was considered significant.
Results
Maternal antibody transfer does not alter fetal viability
In total, 236 pups were analysed in this experiment. The
average number of pups/litter was 12 +/2 3 pups in the group
receiving anti- neurofascin antibody and 11+/2 3 pups/litter in
the control group (p=0,33671), ruling out significant fetal loss due
to the presence of the anti-neurofascin antibody in the mothers’
circulatory system. Birth weight averaged between 4-6 g in both
groups, representing a normal rat birth weight. Sex ratio was 1: 1,5
(male:female) in the neurofascin antibody treated group, 1:1,33 in
the control antibody group and 1: 1,4 in the control group
receiving no treatment at all.
Neurofascin antibodies pass the placental border and
reach the fetal central nervous system
In order to see whether intravenously applied antibody actually
reached the central nervous system (CNS) of the developing fetus,
immunohistochemistry for mouse IgG was performed on pups
sacrificed at E20 of pregnancy. This day of sacrifice was chosen to
assure a high passively transferred antibody titer present in the
mothers’ circulation 48 hours after receiving the second dose of
the anti-neurofascin antibody or the control antibody, respectively.
Strong immunoreactivity for mouse IgG was seen in blood
vessels in the fetal brain, lung, kidney and liver (Fig. 1a, b,c d,
respectively) proving that the antibody had crossed the placental
border and reached the fetal circulation. Negative control slides
(incubated in absence of the primary antibody) showed total
absence of staining (not shown).
Neurofascin staining pattern is not altered by
transplacental exposure to neurofascin antibodies
In normal, untreated adult brain tissue, neurofascin immuno-
reactivity is most pronounced in axons of the hippocampus region
(Fig. 2 a, c) and in purkinje cells and their initial axonal segments
(Fig. 2 b, d). This staining pattern remains unchanged in pups
exposed to neurofascin antibodies in utero (Fig. 2 e–i). Fig. 2e shows
neurofascin immunoreactivity in the hippocampus region at E20,
Fig. 2f and g in the initial axonal segments of purkinje cells at age
p10 in offspring of anti-neurofascin antibody treated mothers.
Fig. 2h and i show neurofascin immunoreactivity at postnatal day
21 in purkinje cells and in axons of the hippocampus region of
neurofascin anibody treated rats, respectively.
The neurofascin staining pattern of the offspring of the rat
mother receiving 260,5 mg anti-neurofascin antibody was virtu-
ally indistinguishable from those receiving the full dose of anti-
neurofascin antibody (data not shown).
Neurofascin antibodies bind to their target structures in
the fetal rat brain
The total absence of any obvious effect of intrauterine exposure
to the anti-neurofascin antibody prompted us to ask the question
whether the transferred autoantibody had actually bound to its
target in the CNS. We performed immunohistochemistry for
combined neurofascin and anti- mouse immunoglobulin for light
microscopy on brain tissue of pups from E20 to up to age 21 days.
Neurofascin antibody treated pups showed a clear double staining
for neurofascin as well as mouse immunoglobulin (Fig. 3a, c), while
animals treated with an isotype matched control antibody directed
against an CNS irrelevant target revealed the normal neurofascin
staining pattern only (Fig. 3 b, d). Single staining for these
antibodies for confocal microscopy of the hippocampus region
(Fig. 3 e–h) confirmed this staining pattern. The staining pattern
for neurofascin is identical in neurofascin antibody treated (e) and
control animals (g), but mouse immunoglobulin is only detectable
in the neurofascin group (f) but not in the control group (h).
Therefore we conclude that the passively transferred antibody
bound to its target in the developing CNS, but this alone did not
lead to any apparent morphological abnormalities.
Pup development and motor performance is not altered
by transplacental anti-neurofascin antibody transfer
Developing pups were monitored closely by three observers
(SH, TP, MH) for up to 6 weeks with respect to growth curve and
motor development. Growth curve was unremarkable in both
groups and virtually indistinguishable to the developmental curve
of fully untreated rat pups (as shown in Fig. 4a). Coordination and
balance tested on an accelerating Rotarod device at age p16, p19,
p24, p25 and p32 failed to detect any statistical significant
differences between the groups (Fig. 4c: untreated control vs.
control antibody group p=0,530163, untreated control vs.
neurofascin treatment p=0,354292, control antibody group vs.
neurofascin group p=0,117562). Similarly, measurement of fore
limb grip strength (Fig. 4d) did not reveal any statistical significant
differences between groups (untreated control vs. control antibody
group p=0,935596, untreated control vs. neurofascin treatment
p=0,429921, control antibody group vs. neurofascin group
p=0,593029). Histological examination of gross morphology at
different developmental stages (E20, p2, p10, p21, p32 and p45)
failed to detect any developmental abnormalities caused by
exposure to the neurofascin-specific antibody (Fig. 2e–i).
Neurofascin- Autoantibodies and Fetal Development
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Discussion
Transplacental transmission of maternal IgG antibodies during
fetal development is a physiological process, starting at the end of
the first trimester. During the second trimester the antibodies can
access the fetal brain resulting in a 50–70 fold increase in IgG in
fetal compared with maternal brains [28]. While in healthy
mothers this provides perinatal immunity to infectious agents, it is
potentially deleterious for children of mothers suffering from
autoimmune diseases such as connective tissue disorders, thyroid
autoimmune disorders, myasthenia gravis, idiopathic thrombocy-
topenic purpura (as reviewed in [31,32]). The time course of
clinical symptomatology often parallels the presumed half life of
IgG immunoglobulins and often will have no long term effects
when the child or mother are treated appropriately. However, this
is not necessarily the case as demonstrated in patients with
systemic lupus erythematosus (SLE). This disease preferentially
affects women in their childbearing years, and in up to 40% of
cases is associated with an autoantibody response to double-
stranded DNA that can cross-react with NMDA-receptors in the
CNS. In a mouse model of the SLE a similar response is associated
with reduced female fetal viability [27], an observation consistent
with available sex ratio data on live births in women with SLE.
Furthermore, children of mothers, but not fathers suffering from
SLE have a high incidence of learning disorders [33–37]. An
observation that led to the demonstration that high titres of DNA/
NMDAR-cross reactive autoantibodies in a mouse model of SLE
induce histological abnormalities in the developing brain that
result in cognitive impairment in adulthood [28].
As Nfasc186 is expressed during CNS development we
speculated maternal autoimmunity to neurofascin might also be
detrimental for developing fetus. This is not a trivial question as
multiple sclerosis is associated with a neurofascin-specific autoan-
tibody response and preferentially affects young women.
In this study, we passively transferred a potentially pathogenic
pan-neurofascin IgG2a mAb into pregnant dams on days 15 and
18 post conception to mimic the physiological concentration of
maternal antibodies into the fetus towards the end of pregnancy.
Our results demonstrate that the passively transferred antibody
crossed the placental barrier and bound to sites at which
neurofascin is expressed in the CNS. However, this was not
sufficient to induce developmental abnormalities as determined by
either histopathological examination or clinical observation. We
conclude that even if anti-neurofascin responses are detected in
pregnant patients these antibodies are unlikely to have a
detrimental effect on fetal development.
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